Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02160990 · ClinicalTrials.gov registry record · Phase 4

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

A Phase 4 study of Obesity, sponsored by Mayo Clinic.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target
1
Study location

NCT02160990: Completed Phase 4 study of Obesity, sponsored by Mayo Clinic.

NCT02160990 is a Phase 4 study of Obesity that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02160990, a Phase 4 study of Obesity, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The overall goal of this study was to determine the effect of exenatide on gastric emptying, satiety and satiation in obese participants. The hypothesis in this study was that exenatide retards gastric emptying in obese patients with baseline accelerated gastric emptying.

Primary Outcome

Gastric emptying of solids half-time is defined as the time for half of the ingested solids to leave the stomach. Subjects were given a scrambled egg breakfast with toast and a glass of milk. The eggs contained a small amount of a radioactive substance. Anterior and posterior gamma camera images were obtain immediately after radiolabeled meal ingestion, every 15 minutes for the first 2 hours, then 30 minutes for the next 2 hours (total 4 hours after the radiolabeled meal).

Conditions Studied

Obesity

Interventions

  • DRUG Placebo
  • DRUG Exenatide

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-06
Est. Completion 2015-03
Phase Phase 4
Mayo Clinic

2,844 total trials

What the finished NCT02160990 record still lists

NCT02160990 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02160990 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT02160990 about?

NCT02160990 is a clinical study titled "Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying". The overall goal of this study was to determine the effect of exenatide on gastric emptying, satiety and satiation in obese participants. The hypothesis in this study was that exenatide retards gastric emptying in obese patients with baseline accelerated gastric emptying.

What is the current status of trial NCT02160990?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2014-06. Estimated completion is 2015-03.

What conditions does trial NCT02160990 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT02160990?

The interventions under investigation include: Placebo (DRUG), Exenatide (DRUG).

Who is sponsoring clinical trial NCT02160990?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02160990 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02160990's enrollment target sits among peer trials

20 946th of 1053 higher than 80 of 1,053 other Obesity trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02160990, the US trial registry maintained by the National Library of Medicine. NCT02160990 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.